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Abstract
With the development of next-generation sequencing technology, there is a great demand for powerful statistical methods
to detect rare variants (minor allele frequencies (MAFs),1%) associated with diseases. Testing for each variant site
individually is known to be underpowered, and therefore many methods have been proposed to test for the association of a
group of variants with phenotypes, by pooling signals of the variants in a chromosomal region. However, this pooling
strategy inevitably leads to the inclusion of a large proportion of neutral variants, which may compromise the power of
association tests. To address this issue, we extend the s-MidP method (Cheung et al., 2012, Genet Epidemiol 36: 675–685)
and propose an approach (named ‘adaptive combination of P-values for rare variant association testing’, abbreviated as
‘ADA’) that adaptively combines per-site P-values with the weights based on MAFs. Before combining P-values, we first
imposed a truncation threshold upon the per-site P-values, to guard against the noise caused by the inclusion of neutral
variants. This ADAmethod is shown to outperform popular burden tests and non-burden tests under many scenarios. ADA is
recommended for next-generation sequencing data analysis where many neutral variants may be included in a functional
region.
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Introduction
Next-generation sequencing acts as a new approach to explore
the genetic basis of complex human diseases [1]. With this new
technology, we are able to identify rare causal variants (minor
allele frequency (MAF),1%) that are not genotyped in genome-
wide association studies (GWAS) but are actually responsible for
part of the heritability of complex diseases. However, the power of
an association test is largely compromised by the low frequencies
of rare causal variants. To increase the power of an association
test, many methods have been proposed to test for the collective
effect of a group of variants in a chromosomal region [2–11].
These methods can be categorized as burden tests and non-burden
tests.
Burden tests pool signals of multiple rare variants within a
functional unit, such as a candidate gene, and then test for the
association between the pooled signal (usually called ‘‘genetic
score’’) and the phenotype [2–5,12]. In the Combined Multivar-
iate and Collapsing (referred to as ‘‘CMC’’) method, a subject’s
genetic score is defined as 1 if he/she has at least one rare variant
in the gene and 0 otherwise [2]. The weighted-sum approach
(referred to as ‘‘WS’’) sums up the variant counts that are inversely
weighted by the standard deviations of the variant frequencies [3].
Morris and Zeggini proposed to construct a genetic score by
accumulating the variant counts in a functional unit (say, a gene or
a pathway) [4], which was a variant of the CMC method. If only
the counts of variants with frequencies smaller than 5% (or 1%)
are aggregated as the genetic score, the test is referred to as ‘‘T5’’
(or ‘‘T1’’). The threshold to discriminate rare variants from
common variants is crucial, but the optimal threshold varies with
the underlying genetic architecture and changes across studies
[12]. The variable threshold (referred to as ‘‘VT’’) approach was
therefore proposed without a preset threshold. Instead, it searches
for the optimal threshold that maximizes the difference between
trait distributions for subjects with and without rare variants [5].
The above methods (including CMC, T1, T5, WS, and VT) are
categorized as ‘‘burden tests’’. These burden tests are more
powerful when rare causal variants in a region have effects on the
phenotype in the same direction, i.e., all are deleterious or all are
protective [13].
On the other hand, non-burden tests, such as the so-called C-
alpha test [9] or the sequence kernel association test (SKAT) [7]
based on a kernel machine regression framework, are more robust
to the inclusion of causal variants with disparate or even opposite
effects on phenotype (we consider SKAT as a representative
method of the non-burden tests, because it is a generalization of
the C-alpha test). However, the non-burden tests such as SKAT can
be less powerful than the burden tests if a large proportion of rare
variants are associated with the phenotype in the same direction
[13]. Because the underlying genetic function of a region is usually
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unknown, choosing an ideal statistical test (burden tests or SKAT)
in advance is impossible. To develop a powerful test that is also
robust to the directions of effects of rare variants, Lee et al. [8]
have proposed an optimal test to combine SKAT [7] and the
burden tests [2–5,12]. This optimal test (referred to as ‘‘SKAT-O’’)
has been shown to outperform the burden tests and SKAT in a
wide range of scenarios [8].
Both the burden tests and the non-burden tests suffer from
power loss with the inclusion of neutral variants. A preferable
method to analyze next-generation sequencing data should have
the robustness to this type of noise. To this end, Cheung et al. [14]
proposed a s-MidP method that combines P-values of individual
variants with the weighting scheme proposed by Madsen and
Browning [3]. To guard against the noise caused by neutral
variants, the s-MidP method excludes the variants with equal rare-
variant counts in cases and in controls. Furthermore, s-MidP uses
the Fisher’s combination of P-values [15] on individual variants
with the Madsen and Browning’s [3] weighting scheme. This
method has been shown to be more powerful than many existing
methods [3–7,9,16,17], when both deleterious and protective
variants, or a large proportion of neutral variants, are present in a
region [14].
Instead of testing for the association of a genetic score (some
linear combination of variant counts) with the phenotype, s-MidP,
inspired by the Fisher’s combination of P-values, can take the
significance of each variant site into account. To simplify, in the
following small example we discuss the Fisher’s combination
method (s-MidP further uses the Madsen and Browning’s [3]
weighting scheme to facilitate the discovery of rare causal
variants). Suppose there are K variants in a region of interest,
the P-values of the K single-variant tests are combined with the
Fisher’s statistic: {2
PK
i~1 log pi [15]. If there is a causal variant
with a P-value of 0.05, it contributes {2 log 0:05ð Þ~5:99 to the
Fisher’s statistic. However, the contribution to the Fisher’s statistic
will be only {2 log 0:5ð Þ~1:39 for a neutral variant with a
P-value of 0.5. Because the P-values of causal variants are usually
smaller than those of neutral variants, the contribution from causal
variants to the Fisher’s statistic is usually more prominent than that
of neutral variants. Thus, different from testing the genetic score
after summing variant counts (including causal variants and
neutral variants), combining P-values after association testing can
strengthen the association signal and guard against the noise
caused by neutral variants.
To more effectively guard against the noise caused by neutral
variants, variants with P-values larger than a threshold (they are
more likely to be neutral) may be truncated (see [18] for the
methodology and [19] for its application). However, the P-value
truncation threshold of 0.05 (used in [19]) may be too stringent,
because testing for each rare variant is usually underpowered
[2,20–22]. For rare variants detection, there is no general rule to
choose a more ‘‘suitable’’ P-value truncation threshold. To address
this issue, we here propose to determine the truncation threshold
adaptively. Therefore, this method is termed ADA (full name:
adaptive combination of P-values for rare variant association
testing), which is inspired by the adaptive combination of P-values
for pathway analysis in GWAS [23]. Instead of fixing a P-value
truncation threshold, the proposed method allows multiple
candidate truncation thresholds (say, 0.10, 0.11, 0.12, …, 0.20)
and works out the optimal threshold for a given data set. The
significance of our test is quantified with permutations. Compre-
hensive simulation studies indicate that the ADA method has a
higher power than s-MidP [14]. It also outperforms some popular
approaches, including the burden tests such as T1, T5, WS, VT
mentioned above, SKAT [7], and SKAT-O [8]. As an application,
the data set from Dallas Heart Study [24,25] is analyzed with the
proposed method.
Materials and Methods
Suppose there are K variants in a region of interest, and the P-
values of testing for the associations of individual variants with the
disease status are p1, p2,    pK , respectively. Without loss of
generality, although we here focus on binary traits, the proposed
method can be applied to continuous traits as well. In rare variants
detection for binary traits, pi’s are commonly obtained by the
Fisher’s exact test [14,26]. Suppose we consider J candidate
truncation thresholds on per-site P-values, h1, h2,    ,hJ . We term
the sites with larger variant frequencies in cases than in controls
‘‘deleterious-inclined variant sites’’. Among the K sites, the
significance score of the deleterious-inclined variant sites is
Szj ~{
XK
i~1
ji:I pivhj
 
:wi log pi, ð1Þ
where ji is an indicator variable coded as 1 if the ith site is
deleterious-inclined and 0 otherwise, I pivhj
 
is an indicator
variable coded as 1 if the ith site has a P-value smaller than hj (the
jth truncation threshold) and 0 otherwise, and wi is a weight given
to the ith site. Following Madsen and Browning [3], we specify
wi~ ni:qi 1{qið Þ½ {
1=2, where qi~
mUi z1
nUi z2
is the frequency for
variant i in the unaffected individuals, nUi is the number of
unaffected individuals genotyped for variant i, and mUi is the
number of mutant alleles observed for variant i in the unaffected
individuals [3]. We recommend using J=11 candidate truncation
thresholds, and we specify h1~0:10, h2~0:11,    , h11~0:20
throughout this study (we will discuss the selection of candidate
truncation thresholds in the Discussion section).
On the other hand, we term the sites with larger variant
frequencies in controls than in cases ‘‘protective-inclined variant
sites’’. Among the K sites, the significance score of the protective-
inclined variant sites is
S{j ~{
XK
i~1
Qi
:I pivhj
 
:wi log pi, ð2Þ
where Qi is an indicator variable coded as 1 if the ith site is
protective-inclined and 0 otherwise. From Equations (1) and (2),
we obtain the significance score accumulated by deleterious-
inclined variants (Szj ) and that accumulated by protective-inclined
variants (S{j ), respectively. A test statistic regardless of the effect
directions (deleterious or protective) is Sj~max S
z
j , S
{
j
 
.
Because variant sites within a functional region are usually not
independent, we need permutations to obtain the P-value of the
observed statistic Sj~max S
z
j , S
{
j
 
, for j=1, …, J. For the bth
permutation (1ƒbƒB), we randomly shuffle the case/control
status and obtain Szj (b) and S
{
j (b) according to Equations (1) and
(2). Then, we obtain the statistic S
(b)
j ~max S
z
j (b),S
{
j (b)
 
, for
j=1, …, J.
With a total of B permutations, we can estimate the P-value of
Sj for the observed sample as
PB
b~1 I S
(b)
j §Sj
 
z1
Bz1
, for each
truncation threshold (j=1, …, J). The P-value of S
(b’)
j for the b’th
Adaptive Combination of P-values
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permutation is estimated by
P
b=b’I S
(b)
j §S
(b’)
j
 
z1
B
, for j=1,
…, J and b’~1,    ,B. We can then find the minimum P-value
MinP across the J candidate truncation thresholds for the
observed sample, and the minimum P-value MinP(b) for the bth
permuted samples (b=1,…, B). For the observed and permuted
samples, MinP and MinP(b) (b=1,…, B) are P-values obtained
from the ‘‘optimal’’ truncation thresholds that yield the most
significant results (or, the minimum P-values) across candidate
truncation thresholds. These ‘‘optimal’’ thresholds may vary across
permuted samples, in order to preserve the validity of the proposed
method. We then compare MinP with MinP(b) (b=1,…, B) to
assess the significance of the observed sample. The ‘‘adjusted P-
value’’ is calculated by
PB
b~1 I MinP
(b)ƒMinP
 
z1
Bz1
. This
method is referred to as ‘‘ADA’’, because the per-site P-values of
variant sites are combined adaptively. Figure 1 is a workflow
diagram of the ADA method.
Simulation Study
With the Cosi program [27], we first generated 200 data sets,
each containing 10,000 chromosomes of 1 Mb regions. The Cosi
program is based on the coalescent population genetic model [28]
and is widely used to simulate human genome sequences. The
chromosomes were generated according to the linkage disequilib-
rium patterns of the HapMap CEU (Utah residents with ancestry
from northern and western Europe) samples. We randomly
specified 25% of the variants with population MAF,1% to be
causal variants. A region containing d causal variants was
randomly selected as the causal region, where d=3, 5, 10, 15,
or 20. On average, a causal region spanned ,3.6, ,6.4, ,12.8,
,19.2, and ,25.6 kb, for d=3, 5, 10, 15, and 20, respectively.
The numbers of neutral variants were ,60, ,100, ,200, ,300,
,400, for the regions spanning ,3.6, ,6.4, ,12.8, ,19.2, and
,25.6 kb, respectively. Across the 200 simulated data sets, the
proportions of causal variants among all non-synonymous variants
ranged from ,4% to ,8%. We randomly assigned risk % of the d
causal variants as deleterious variants, and let the remaining
100{riskð Þ% causal variants be protective variants. The value of
risk was set at 5, 20, 50, 80, and 100, respectively. In this way, we
considered the simulation settings with mixtures of deleterious and
protective variants. The population attributable risk (PAR) of each
causal variant was specified at 0%, 0.1%, …, 0.5%, respectively.
Following the simulation setting of previous studies [3,29–31],
the genotype relative risk (GRR) of the jth causal variant is:
GRRj~
PARj
1{PARj
 
:MAFj
z1
 ! {1ð ÞI jj~1 
, ð3Þ
where PARj and MAFj are the PAR and the population MAF of
that variant, respectively. The indicator function I jj~1
 
is 1 if
the jth causal variant is protective, and is 0 if deleterious. Figure S1
shows the distributions of population MAFs and GRRs of the
causal variants in our 200 simulated data sets. Because we focused
on the detection of rare causal variants, the population MAFs of
the causal variants were all smaller than 1% in our simulation. To
generate the genotypes of a subject, we randomly selected two
chromosomes from the pool of 10,000 chromosomes. The disease
status of a subject with chromosomes H1,H2f g was determined by
P affected D H1,H2f gð Þ~f0| P
2
k~1
P
d
j~1
GRR
I Hk, j~aj
 
j ð4Þ
[29–31], where f0 was the baseline penetrance, and aj was the
minor allele at the jth causal variant site. Following Cheung et al.
[14], f0 was specified at 1%, and the sample size was set at 1000.
Pairs of chromosomes were drawn from the chromosome pool
with replacement until 500 cases and 500 controls were sampled.
Tests under Comparison
We compared ADA with s-MidP [14], burden tests, and non-
burden tests. Cheung et al.’s [14] R script was used to implement
their s-MidP method (http://www.columbia.edu/,sw2206/
softwares.htm). We followed the default of the s-MidP R script,
single-nucleotide polymorphisms with MAF.5% in the combined
sample of cases and controls were excluded from the analyses of
s-MidP and ADA. To have a fair comparison between these two
methods, the P-values used in Equations (1) and (2) (i.e., pi’s) are
obtained by the mid P-values according to the Fisher’s exact test
[14,26].
Four burden tests including the fixed-threshold approach with
MAF thresholds of 1% and 5% (i.e., ‘‘T1’’ and ‘‘T5’’, respectively)
[4], the weighted-sum approach (i.e., ‘‘WS’’) [3], and the variable-
threshold approach (i.e., ‘‘VT’’) were implemented with the R
script by Price et al. [5] (http://genetics.bwh.harvard.edu/
rare_variants/). Because VT needs permutations to get P-values,
Price et al. [5] performed permutations for all the four tests (VT,
WS, T1, and T5) in their R script, at almost no extra
Figure 1. The workflow diagram of the ADA method.
doi:10.1371/journal.pone.0085728.g001
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computational cost. Note that the original VT script performs
right-tailed tests for all the four methods, and therefore they are
underpowered when risk is low. We modified the original VT script
to perform two-tailed tests and used the revised R script to
implement the four burden tests.
Two non-burden tests including the sequence kernel association
test (i.e., ‘‘SKAT’’) [7] and the optimal test (i.e., ‘‘SKAT-O’’) [8] that
optimally combines the burden tests and SKAT were implemented
with the R package ‘‘SKAT’’ [32]. We used the default weight
function in the package ‘‘SKAT’’, wj~Beta MAFj ,1,25
 
, as the
weight given to the jth variant site with MAF of MAFj .
The P-values of ADA, s-MidP, VT, WS, T1, and T5 were
obtained with 10,000 permutations when evaluating the type-I
error rates and 1,000 permutations when evaluating power,
respectively. For SKAT and SKAT-O, we used the default method
in the package ‘‘SKAT’’ to compute P-values, which was an exact
method that computed P-values by inverting the characteristic
function of the mixture chi-square distribution [33].
Results
Type-I Error Rates
By setting the PAR at exactly 0% and using ,25.6 kb regions,
we evaluated type-I error rates by performing 1,000 replications
for each of the 200 simulated data sets. Based on the 200,000
( = 200|1000) replications across the 200 simulated data sets,
Table 1 shows that all of the eight tests are valid in the sense that
their type-I error rates match the nominal significance levels.
Power Comparisons
When we evaluated power, a total of 100 replications were
performed under each scenario (each combination of risk, PAR,
and d) for each of the 200 simulated data sets. Figure 2 presents the
power averaged over the 200 data sets, where 100 replications
were performed for each data set. Each point represents the result
averaged from 200|100~20,000 replications performed for
some combination of risk, PAR, and d. The nominal significance
level was set at 0.05 (top row) and 0.01 (bottom row), respectively.
In the first column of Figure 2, power was assessed with a varying
risk, a fixed PAR (0.3%), and a fixed d (20).
Note that the lowest power occurs around risk~20% (among
the five values of risk), rather than risk~50% (the first column of
Figure 2). This is because, in our simulation setting (following
[29]), a deleterious variant has a larger effect size than a protective
variant, given that they have the same MAF. For simplicity of
illustration, we consider only one causal variant site. The
probability that a subject has two rare variants at this site is
extremely small and thus can be ignored. Equation (4) can be
simplified as
P affected D H1,H2f gð Þ~f0|GRR,
where f0 is the baseline penetrance and GRR is the genotype
relative risk of the causal variant. Based on Equation (3),
GRR~
PAR
1{PARð Þ:MAFz1
 	 {1ð ÞI j~1ð Þ
,
where the subscripts have been removed for simplification. Let
C~ PAR
1{PARð Þ:MAFz1. For case-control studies, the odds ratio (OR)
of being affected among subjects who have a causal variant versus
those who do not is an appropriate measure for effect size. Let
ORd be the OR of being affected among subjects who have a
deleterious variant versus those who do not. We have
ORd~
f0C
1{f0C
f0
1{f0
w1:
Let ORp be the OR of being affected among subjects who have a
protective variant versus those who do not. We have
ORp~
f0C
{1
1{f0C{1
f0
1{f0
v1:
Because C{1ð Þ2w0,
C2{2Cz1w0, f0C2{2f0Czf0w0
f0C{2f0zf0C
{1w0, 1{2f0zf 20w1{f0C
{1{f0Czf
2
0
1{f0ð Þ2w 1{f0Cð Þ 1{f0C{1
 
,
1{f0
1{f0C
w 1{f0C
{1
1{f0
f0C
1{f0C
f0
1{f0
w
f0
1{f0
f0C
{1
1{f0C{1
, ORdw
1
ORp
:
Table 1. Type-I error rates.
nominal
significance level 0.0001 0.005 0.010 0.015 0.020 0.025 0.030 0.035 0.040 0.045 0.050
SKAT-O 0.0001 0.0054 0.0102 0.0151 0.0196 0.0246 0.0295 0.0347 0.0396 0.0444 0.0492
SKAT 0.0001 0.0048 0.0096 0.0142 0.0191 0.0237 0.0288 0.0337 0.0384 0.0434 0.0482
s-MidP 0.0001 0.0050 0.0101 0.0149 0.0199 0.0248 0.0298 0.0348 0.0398 0.0448 0.0498
ADA 0.0001 0.0050 0.0100 0.0148 0.0199 0.0247 0.0297 0.0351 0.0400 0.0451 0.0500
T1 0.0001 0.0046 0.0096 0.0146 0.0196 0.0245 0.0294 0.0346 0.0399 0.0449 0.0501
T5 0.0001 0.0046 0.0098 0.0149 0.0198 0.0247 0.0296 0.0346 0.0398 0.0449 0.0498
WS 0.0001 0.0052 0.0103 0.0153 0.0204 0.0254 0.0304 0.0356 0.0402 0.0452 0.0502
VT 0.0001 0.0050 0.0100 0.0150 0.0201 0.0250 0.0302 0.0352 0.0404 0.0453 0.0503
doi:10.1371/journal.pone.0085728.t001
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Thus, in our simulation setting (following [29]), a deleterious
variant has a larger effect size than a protective variant, given that
they have the same MAF. This is why the lowest power occurs at
risk smaller than 50%.
In the second column, PAR varied, while d was fixed at 20 and
risk % was fixed at 80%. The setting of risk % (80%) was chosen
because regulatory sequences are likely to contain many more
deleterious variants than protective variants [34,35]. As for the
third column, power was compared while d was varying, but risk %
was fixed at 80%, and PAR was fixed at 0.3%. ADA test showed
the best performance under the majority of simulation scenarios.
Application to Data from Dallas Heart Study
We applied the eight tests to a population-based resequencing
study for the ANGIOPOIETIN–LIKE 4 (ANGPTL4) gene [24,25].
To learn the role of ANGPTL4 in plasma triglyceride levels,
Romeo et al. [24,25] sequenced seven exons and the intron-exon
boundaries of ANGPTL4. The important confounders when
investigating plasma triglyceride levels include ethnicity, age, sex,
and body-mass index (BMI) [24]. To remove the potential
influence of ethnicity on triglyceride, we only analyzed the 1,045
European Americans from the total 3,551 subjects sampled from
Dallas County residents [36]. The log-transformed triglyceride
levels were adjusted for age, sex, and BMI, with a linear
regression. The regression residuals were treated as new pheno-
types that have been adjusted for important confounders. Subjects
with residuals larger than the 70th percentile and smaller than the
30th percentile were treated as cases and controls, respectively.
Then the subjects with missing genotypes were removed from our
analysis. Finally, we had 179 cases and 213 controls (the numbers
of cases and controls were not necessarily equal, because we
removed the subjects with missing genotypes after marking the
30th and 70th percentiles of the phenotype).
We then applied the eight tests to this data set. The variants
with MAF,5% in the ANGPTL4 gene were analyzed to test for
their associations with triglyceride. The significant association of
ANGPTL4 with triglyceride was previously reported by other
investigators [14,37]. With a significance level of 0.05, the four
burden tests (VT, WS, T1, and T5) did not show significant
association of ANGPTL4 with triglyceride, whereas the other four
tests including ADA, SKAT, SKAT-O, and s-MidP confirmed this
association (see Table 2).
Discussion
In this work, we have proposed a powerful ADA method for rare
causal variants detection. Instead of fixing a threshold to truncate
P-values, we recommend searching for the ‘‘optimal’’ threshold
from among multiple candidate truncation thresholds. The
Figure 2. Comparison of power by risk (the percentage of deleterious variants among the d causal variants), PAR, and d (the number
of causal variants). The figure shows the power comparison by risk (left column, given PAR= 0.3% and d=20), PAR (middle column, given d= 20
and risk= 80%), and d (right column, given risk= 80% and PAR= 0.3%). The nominal significance level was set at 0.05 (top row) and 0.01 (bottom row),
respectively.
doi:10.1371/journal.pone.0085728.g002
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validity of ADA is preserved because we allow the permuted and
observed data to have different ‘‘optimal’’ truncation thresholds.
Here, we use 11 candidate P-value truncation thresholds, 0.10,
0.11, 0.12, …, 0.20. We do not consider a more stringent
threshold (,0.10), because testing for a single rare variant is
usually underpowered [2,20–22] and a stringent threshold may
exclude the information of causal variants. We neither consider a
more liberal threshold (.0.20), because that may include more
noise from neutral variants. To show this, we also evaluated the
ADA method with 21 candidate P-value truncation thresholds
(0.05, 0.06, 0.07, …, 0.25). Table 3 lists the power of the ADA
method with two sets of candidate P-value truncation thresholds.
Using 21 candidate P-value truncation thresholds (0.05, 0.06, 0.07,
…, 0.25) does not contribute a noticeable power gain to ADA.
Note that the statistic, Sj~max S
z
j , S
{
j
 
, is the maximization
of the score accumulated by deleterious-inclined variants and that
accumulated by protective-inclined variants. Another justifiable
statistic is Szj zS
{
j
 
, which is more powerful than ADA when
the numbers of deleterious and protective variants are compara-
ble, but it is less powerful when the region contains more
deleterious variants than protective variants (or, more protective
variants than deleterious variants). Because both evolutionary
mechanisms and empirical studies support the hypothesis that
regulatory sequences contain substantial amounts of weakly
deleterious variation [34,35,38,39], the number of deleterious
variants may surpass that of protective variants in most situations.
Therefore, we still advocate using max Szj , S
{
j
 
, rather than
Szj zS
{
j
 
.
The computation time of ADA is slightly longer than that of
s-MidP. For simulated data sets each containing 500 cases and 500
controls in ,3.6 kb regions (include ,60 nonsynonymous variant
sites), s-MidP (http://www.columbia.edu/,sw2206/softwares.
htm) with 1000 permutations on average needs ,27.8 sec, ADA
with 1000 permutations needs ,28.6 sec, SKAT-O needs
,6.7 sec, while VT with 1000 permutations takes only ,0.9 sec.
When the region was enlarged to ,6.4 kb (include ,110
nonsynonymous variant sites), s-MidP with 1000 permutations
on average needs ,45.3 sec, ADA with 1000 permutations needs
,45.9 sec, SKAT-O needs ,9.2 sec, while VT with 1000
permutations takes 1.2 sec. These were measured on a Linux
platform with an Intel Xeon E5-2690 2.9 GHz processor and
2 GB memory. Although the computation time of VT or SKAT-O
is much shorter than that of ADA (or s-MidP), the power of VT or
SKAT-O is not comparable to ADA.
Rare causal variants are likely to play an important role in the
etiology of some complex diseases [40–45], but they are difficult to
detect by single-locus tests [2,20–22]. Grouping variant sites in a
functional region and testing for association with an omnibus
statistic is a promising strategy. Compared with the burden tests
(VT, WS, T1, and T5) and the non-burden tests (SKAT and SKAT-
O) evaluated here, ADA is more robust to the inclusion of neutral
variants. With the advancement in next-generation sequencing
technology, all single-nucleotide variants (causal or neutral) can be
sequenced. ADA is recommended for its ability to guard against the
noise of neutral variants.
Supporting Information
Figure S1 The distributions of the populationminor allele
frequencies (MAFs) and genotype relative risks (GRRs) of
the causal variants in our 200 simulated data sets.
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Table 3. Power (%) of the ADA method with two sets of candidate P-value truncation thresholds.
candidate P-value
truncation thresholds Given PAR=0.3% and d=20 Given d=20 and risk=80% Given risk=80% and PAR=0.3%
risk (%) PAR (%) d
5 20 50 80 100 0.0 0.1 0.2 0.3 0.4 0.5 3 5 10 15 20
Nominal significance level = 5%
0.10, 0.11,… 0.20 29.97 23.17 33.28 67.41 88.24 4.84 18.45 45.06 67.41 82.03 90.47 14.00 24.16 40.58 55.80 67.41
0.05, 0.06,…, 0.25 29.38 23.50 35.04 68.73 89.31 5.04 18.56 46.09 68.73 83.60 91.91 14.64 25.50 42.24 57.30 68.73
Nominal significance level = 1%
0.10, 0.11,…, 0.20 13.00 8.17 17.99 51.10 78.32 1.00 8.39 29.50 51.10 68.09 80.03 4.68 10.99 24.01 38.65 51.10
0.05, 0.06,…, 0.25 12.25 8.22 18.74 51.98 79.17 0.93 8.46 30.03 51.98 69.45 81.22 4.88 11.50 24.93 39.59 51.98
doi:10.1371/journal.pone.0085728.t003
Table 2. Analysis of the Dallas Heart Study data.
SKAT-O SKAT s-MidPa ADAa T1a T5a WSa VTa
P-value 0.024 0.012 0.028 0.011 0.584 0.070 0.184 0.486
aP-values were estimated based on 104 permutations.
doi:10.1371/journal.pone.0085728.t002
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